These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2085733)

  • 1. Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier.
    Riachi NJ; Dietrich WD; Harik SI
    Brain Res; 1990 Nov; 533(1):6-14. PubMed ID: 2085733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of MPTP neurotoxicity in vivo with oxidation of MPTP by the brain and blood-brain barrier in vitro in five rat strains.
    Riachi NJ; Behmand RA; Harik SI
    Brain Res; 1991 Jul; 555(1):19-24. PubMed ID: 1933326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity.
    Kalaria RN; Mitchell MJ; Harik SI
    Proc Natl Acad Sci U S A; 1987 May; 84(10):3521-5. PubMed ID: 3495000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entry of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine into the rat brain.
    Riachi NJ; LaManna JC; Harik SI
    J Pharmacol Exp Ther; 1989 Jun; 249(3):744-8. PubMed ID: 2786562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity. II. Susceptibility among mammalian species correlates with the toxin's metabolic patterns in brain microvessels and liver.
    Riachi NJ; Harik SI; Kalaria RN; Sayre LM
    J Pharmacol Exp Ther; 1988 Feb; 244(2):443-8. PubMed ID: 3258032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents.
    Sundström E; Samuelsson EB
    Pharmacol Toxicol; 1997 Nov; 81(5):226-31. PubMed ID: 9396088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat.
    Harik SI; Schmidley JW; Iacofano LA; Blue P; Arora PK; Sayre LM
    J Pharmacol Exp Ther; 1987 May; 241(2):669-76. PubMed ID: 2437293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strain differences in systemic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in mice correlate best with monoamine oxidase activity at the blood-brain barrier.
    Riachi NJ; Harik SI
    Life Sci; 1988; 42(23):2359-63. PubMed ID: 3259663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance of the golden hamster to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-neurotoxicity is not only related with low levels of cerebral monoamine oxidase-B.
    Rodríguez S; Ito T; He XJ; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):127-33. PubMed ID: 21795029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity.
    Zuddas A; Fascetti F; Corsini GU; Piccardi MP
    Exp Neurol; 1994 May; 127(1):54-61. PubMed ID: 8200437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional localization of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) uptake: mismatch between its uptake and neurotoxic sites.
    Takada M; Campbell KJ; Hattori T
    Neurosci Lett; 1991 Nov; 133(1):137-40. PubMed ID: 1665214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of MPTP and its pyridinium metabolites on monoamine uptake and on central catecholamine neurons in mice.
    Jonsson G; Nwanze E; Luthman J; Sundström E
    Acta Physiol Scand; 1986 Oct; 128(2):187-94. PubMed ID: 3535380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obligatory role for complex I inhibition in the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Richardson JR; Caudle WM; Guillot TS; Watson JL; Nakamaru-Ogiso E; Seo BB; Sherer TB; Greenamyre JT; Yagi T; Matsuno-Yagi A; Miller GW
    Toxicol Sci; 2007 Jan; 95(1):196-204. PubMed ID: 17038483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
    Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
    Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between the neostriatal content of the 1-methyl-4-phenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice.
    Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
    J Pharmacol Exp Ther; 1991 May; 257(2):691-7. PubMed ID: 2033514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration.
    Giovanni A; Sieber BA; Heikkila RE; Sonsalla PK
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1000-7. PubMed ID: 7932147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetaldehyde directly enhances MPP+ neurotoxicity and delays its elimination from the striatum.
    Zuddas A; Corsini GU; Schinelli S; Barker JL; Kopin IJ; di Porzio U
    Brain Res; 1989 Oct; 501(1):11-22. PubMed ID: 2804689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection and potentiation of MPTP-induced toxicity by cytochrome P-450 inhibitors and inducer: in vitro studies with brain slices.
    Pai KS; Ravindranath V
    Brain Res; 1991 Aug; 555(2):239-44. PubMed ID: 1933335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different susceptibility to 1-methyl-4-phenylpyridium (MPP(+))-induced nigro-striatal dopaminergic cell loss between C57BL/6 and BALB/c mice is not related to the difference of monoamine oxidase-B (MAO-B).
    Ito T; Suzuki K; Uchida K; Nakayama H
    Exp Toxicol Pathol; 2013 Jan; 65(1-2):153-8. PubMed ID: 21855308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.